人乳头瘤病毒阳性口咽癌治疗后PET-CT监测的成本效果分析
该成本效果分析构建马尔可夫决策模型,从第三方支付方视角比较人乳头瘤病毒阳性口咽鳞状细胞癌患者治疗后临床监测联合PET/CT与单纯临床监测的成本效果,采用1年周期和30年时间跨度。结果显示联合策略的增量成本效果比为每获得一个质量调整生命年89850美元,当PET/CT费用不超过1678美元时,原发治疗后6个月内单次PET/CT监测仍具成本效果。
要点
- 联合PET/CT监测较单纯临床监测的增量成本效果比为每质量调整生命年89850美元。
- 临床监测中软性纤维内镜灵敏度需超过51%或PET/CT费用超过1678美元,单纯临床监测才更具成本效果。
- 影像监测与临床监测成本效果相等时的支付意愿阈值约为每质量调整生命年80000美元。
核心结论
- 尽管人乳头瘤病毒阳性口咽癌复发率较低,原发治疗后6个月内单次PET/CT监测在费用不超过1678美元时仍是常规监测中具成本效果的工具。
- 该策略的成本效果还取决于临床监测(软性纤维咽喉镜)的灵敏度和因国家而异的支付意愿阈值。
研究设计与样本
- 成本效果分析,构建马尔可夫决策模型,从第三方支付方视角分析,采用1年马尔可夫周期和30年时间跨度。
- 比较两种治疗后监测策略:临床监测联合PET/CT扫描与单纯临床监测,对象为人乳头瘤病毒阳性口咽鳞状细胞癌患者。
- 转移概率、成本、健康效用值及其研究范围来自文献。
- 研究场景为美国具有头颈肿瘤外科医生和医师的肿瘤诊疗中心。
主要发现
- PET/CT联合临床监测对比单纯临床监测的增量成本效果比为每获得一个质量调整生命年89850美元。
- 临床监测中软性纤维内镜灵敏度需超过51%,或PET/CT扫描费用需超过1678美元,单纯临床监测才更具成本效果。
- 影像监测与临床监测成本效果相等时的支付意愿阈值约为每质量调整生命年80000美元。
关键数值与推荐
- 增量成本效果比:PET/CT联合临床监测对比单纯临床监测为每质量调整生命年89850美元。
- 软性纤维内镜灵敏度阈值:需超过51%,单纯临床监测才更具成本效果。
- PET/CT费用阈值:需超过1678美元,单纯临床监测才更具成本效果。
- 支付意愿阈值:影像监测与临床监测成本效果相等时约为每质量调整生命年80000美元。
临床怎么用
- 原发治疗后6个月内单次PET/CT监测在费用不超过1678美元时仍具成本效果。
- 该策略的成本效果取决于临床监测(软性纤维咽喉镜)的灵敏度和因国家而异的支付意愿阈值。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine the cost-effectiveness of surveillance imaging with PET/CT scan among patients with human papillomavirus-positive oropharyngeal squamous cell carcinoma. STUDY DESIGN: Cost-effectiveness analysis. SETTING: Oncologic care centers in the United States with head and neck oncologic surgeons and physicians. METHODS: We compared the cost-effectiveness of 2 posttreatment surveillance strategies: clinical surveillance with the addition of PET/CT scan versus clinical surveillance alone in human papillomavirus-positive oropharyngeal squamous cell carcinoma patients. We constructed a Markov decision model which was analyzed from a third-party payer's perspective using 1-year Markov cycles and a 30-year time horizon. Values for transition probabilities, costs, health care utilities, and their studied ranges were derived from the literature. RESULTS: The incremental cost-effectiveness ratio for PET/CT with clinical surveillance versus clinical surveillance alone was $89,850 per quality-adjusted life year gained. Flexible fiberoptic scope exams during clinical surveillance would have to be over 51% sensitive or PET/CT scan cost would have to exceed $1678 for clinical surveillance alone to be more cost-effective. The willingness-to-pay threshold at which imaging surveillance was equally cost-effective to clinical surveillance was approximately $80,000/QALY. CONCLUSION: Despite lower recurrence rates of human papillomavirus-positive oropharyngeal cancer, a single PET/CT scan within 6 months after primary treatment remains a cost-effective tool for routine surveillance when its cost does not exceed $1678. The cost-effectiveness of this strategy is also dependent on the clinical surveillance sensitivity (flexible fiberoptic pharyngoscopy), and willingness-to-pay thresholds which vary by country.
引用
- Lin ME, Castellanos CX, Acevedo JR, et al. Cost-Effectiveness Analysis of PET-CT Surveillance After Treatment of Human Papillomavirus-Positive Oropharyngeal Cancer. Otolaryngol Head Neck Surg. 2023. PMID: 37622527. doi:10.1002/ohn.483
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。